Literature DB >> 18086633

Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.

Quan Liao1, Yu-Pei Zhao, Ying-Chi Yang, Li-Jun Li, Xiao Long, Shao-Mei Han.   

Abstract

BACKGROUND: The differential diagnosis of solid lesions located at the pancreatic head is very important for choosing therapies and setting up surgical tactics. This study was designed to evaluate the clinical significance of combined measurement of multiple serum tumor markers and the application of the receiver-operating characteristic (ROC) curves in the differential diagnosis of solid lesions located at the pancreatic head.
METHODS: The serum levels of CA19-9, CA242, CA50 and carcinoembryonic antigen (CEA) in 112 patients with carcinoma of the pancreatic head and 38 patients with focal chronic pancreatitis in the pancreatic head were measured with ELISA. The sensitivity, specificity, positive likelihood ratio (PLR) and negative likelihood ratio (NLR) of the four serum tumor markers were calculated. The ROC curves for the four serum tumor markers were constructed and the area under the curve (AUC) was calculated.
RESULTS: The AUCs of CA19-9, CA242, CA50 and CEA were 0.805, 0.749, 0.738 and 0.705; the PLRs were 1.91, 3.43, 5.09 and 5.46; and the NLRs were 0.41, 0.56, 0.59 and 0.71, respectively. Combined measurements increased the diagnostic specificity, and parallel combined testing increased the diagnostic sensitivity.
CONCLUSIONS: Combined measurement of serum tumor markers CA19-9, CA242, CA50 and CEA is valuable in differential diagnosis of solid lesions located at the pancreatic head, and CA19-9 has the best diagnostic ability. Combined measurements can increase the specificity of diagnosis. Evaluation with the ROC curve is better than the sensitivity or specificity alone and the results are more integrated and objective.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086633

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  25 in total

1.  Prognostic value of the neutrophil-to-lymphocyte ratio for overall and disease-free survival in patients with surgically treated esophageal squamous cell carcinoma.

Authors:  Joonho Jung; Seong Yong Park; Soo-Jin Park; Jiye Park
Journal:  Tumour Biol       Date:  2015-12-12

2.  Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma.

Authors:  Shun Zhang; Yi-Ming Wang; Chuan-Dong Sun; Yun Lu; Li-Qun Wu
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

3.  Quantitative assessment of the diagnostic role of MUC1 in pancreatic ductal adenocarcinoma.

Authors:  Siliang Wang; Xiaodong Chen; Meiyue Tang
Journal:  Tumour Biol       Date:  2014-06-11

Review 4.  Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.

Authors:  Si-Biao Su; Shan-Yu Qin; Wen Chen; Wei Luo; Hai-Xing Jiang
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

5.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

6.  CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.

Authors:  Victor Molina; Laura Visa; Carles Conill; Salvador Navarro; Jose M Escudero; Jose M Auge; Xavier Filella; Miguel A Lopez-Boado; Joana Ferrer; Laureano Fernandez-Cruz; Rafael Molina
Journal:  Tumour Biol       Date:  2011-12-29

Review 7.  Serum sialylation changes in cancer.

Authors:  Zejian Zhang; Manfred Wuhrer; Stephanie Holst
Journal:  Glycoconj J       Date:  2018-04-21       Impact factor: 2.916

Review 8.  Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis.

Authors:  Yimin Zhang; Jun Yang; Hongjuan Li; Yihua Wu; Honghe Zhang; Wenhu Chen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

9.  CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis.

Authors:  Ji-Cong Gui; Wei-Li Yan; Xing-Dang Liu
Journal:  Clin Exp Med       Date:  2013-03-03       Impact factor: 3.984

Review 10.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Authors:  Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.